It’s normal to have uric acid in your body, but too much can increase your risk for gout – an extremely painful form of inflammatory arthritis that often presents with other health issues, including kidney disease, heart disease, diabetes and permanent joint and tissue damage. Despite this, just 10 percent of gout sufferers are being properly treated – and more than one-third have not had their uric acid checked in the past five years.
To raise awareness about the need for timely treatment for gout – including regular monitoring of serum uric acid (sUA) levels – the Gout & Uric Acid Education Society (GUAES) has introduced a new “Go for Six” campaign. The campaign urges those who have or who are at risk for gout to get their sUA levels checked every six months, and to work with their doctor to determine a treatment plan for controlling gout and keeping sUA levels to a healthy 6 mg/dL or below.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7420351-gout-uric-acid-go-for-six-campaign/
Denny’s, one of America’s largest full-service restaurant chains, today announced its commitment to sourcing and serving 100 percent cage-free eggs in all of its U.S. restaurants by 2026. Denny’s is the first within the family dining segment to commit to 100% cage-free eggs, underlining the brand’s dedication to the humane treatment of animals within its supply sourcing and its ongoing focus on quality, flavor and guest satisfaction.
“We believe our guests care about how their food is sourced and so do we. For more than 60 years, we have listened to our guests to understand what they care about the most, without sacrificing on quality, taste or value,” said John Miller, Denny’s president and chief executive officer. “The humane treatment of animals remains an important part of our brand’s sourcing strategy, and our commitment to this transition underscores our confidence in the ethical evolution of supplier capabilities.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7731351-denny-s-commits-cage-free-eggs/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Crystal Lagoons broke the record for the “World's Largest Crystalline Lagoon” with the completion of its latest project in Egypt.
Twelve Crystal Lagoons totaling 250 acres will be the centerpiece of the $5.5 billion dollar, 1,850-acre development in Citystars Sharm El Sheikh. The record-breaking lagoon is 30 acres of crystal-clear water surrounded by white sandy beaches - perfect for swimming, sailing, kayaking and more.
Citystars Sharm el Sheikh's crystal lagoon get its salt water supply from wells in the middle of the desert that are otherwise useless, allowing for a tropical crystalline lagoon in the desert. In addition, the salt water used in the crystal lagoon features higher levels of purity and will be used for reverse osmosis desalinization processes, lowering the costs of water treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7689951-crystal-lagoons-guinness-world-record/
The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education facility to expand their services further. These expansions are part of constant improvements that have been occurring for the last 15 years, alongside high quality service.
The area of the clinic has increased by ten-fold to approximately 1800 m2 during the years. Moreover, the oral surgery division was opened in 2015, so eight dental treatment rooms and four oral surgery rooms are now in place today. All of the surgery rooms can serve ambulatory oral surgery treatments. The ImplantCenter is unique in Hungarian private dentistry because they can implement more complex treatments in the framework of one-day oral surgery procedure. This is due to the big and fully equipped operating room opened in November 2017. As part of the service, the ImplantCenter offers one and two-bed private rooms with medical supervision to their patients after each surgery.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8274651-implantcenter-hungarian-dental-service/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Asia-Pacific
Dr. Jeong Chan-woo from South Korea
Sharing skin love - Skin Health Promotion for Orphanage and for low-income children/youth
This initiative was established to help children from low-income families, without parents or those living away from their parents, to receive education on how to prevent skin diseases. They also have access to high quality treatment if they are suffering from a dermatological condition.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are once again teaming up to hit home runs for prostate cancer research and encourage fans to “Keep Dad in the Game” as part of the yearly celebration of Father’s Day and annual Home Run Challenge.
This year Joe Torre, MLB’s Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encourages baseball fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”
“Joe has been a great partner in our progress toward improved treatment outcomes and an eventual cure,” said PCF Founder and Chairman Mike Milken. “His work as well as those by MLB and all 30 Clubs has helped us raise more than $45 million for research programs that are saving thousands of lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7729251-pcf-and-mlb-prostate-home-run-challenge/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
